Corvus Pharmaceuticals Inc (NASDAQ:CRVS) Receives $10.67 Consensus Target Price from Analysts

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) has earned an average rating of “Hold” from the seven ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $10.67.

Several equities research analysts have recently issued reports on the stock. Roth Capital assumed coverage on shares of Forty Seven in a research note on Wednesday, May 29th. They set a “buy” rating and a $28.00 price target for the company. Zacks Investment Research lowered shares of General Finance from a “buy” rating to a “hold” rating in a research note on Monday, July 15th.

In other Corvus Pharmaceuticals news, Director Orbimed Advisors Llc acquired 657,344 shares of Corvus Pharmaceuticals stock in a transaction that occurred on Monday, July 1st. The stock was acquired at an average cost of $3.72 per share, for a total transaction of $2,445,319.68. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Richard A. Md Miller acquired 15,212 shares of Corvus Pharmaceuticals stock in a transaction that occurred on Tuesday, June 11th. The stock was acquired at an average price of $3.49 per share, with a total value of $53,089.88. The disclosure for this purchase can be found here. Insiders purchased a total of 730,534 shares of company stock valued at $2,695,804 over the last quarter. 40.40% of the stock is owned by company insiders.



Institutional investors have recently added to or reduced their stakes in the stock. Raymond James Trust N.A. bought a new position in Corvus Pharmaceuticals in the 1st quarter valued at $53,000. Paloma Partners Management Co bought a new position in Corvus Pharmaceuticals in the 4th quarter valued at $58,000. Rhumbline Advisers boosted its holdings in Corvus Pharmaceuticals by 44.1% in the 4th quarter. Rhumbline Advisers now owns 18,203 shares of the company’s stock valued at $67,000 after purchasing an additional 5,570 shares during the period. Prudential Financial Inc. boosted its holdings in Corvus Pharmaceuticals by 15.0% in the 4th quarter. Prudential Financial Inc. now owns 21,545 shares of the company’s stock valued at $79,000 after purchasing an additional 2,805 shares during the period. Finally, Millennium Management LLC boosted its holdings in Corvus Pharmaceuticals by 61.2% in the 4th quarter. Millennium Management LLC now owns 60,248 shares of the company’s stock valued at $221,000 after purchasing an additional 22,878 shares during the period. Institutional investors and hedge funds own 84.46% of the company’s stock.

Shares of CRVS stock traded up $0.44 during trading hours on Tuesday, hitting $6.05. 257,836 shares of the company were exchanged, compared to its average volume of 385,428. The company’s fifty day moving average price is $4.39. The company has a quick ratio of 12.39, a current ratio of 12.39 and a debt-to-equity ratio of 0.03. Corvus Pharmaceuticals has a 52-week low of $3.22 and a 52-week high of $11.23.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.40). As a group, equities analysts expect that Corvus Pharmaceuticals will post -1.61 EPS for the current year.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

See Also: What is the Dow Jones Industrial Average (DJIA)?

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.